Skip to main content
BioCentury Innovations (formerly SciBX)
< Next Issue 1 2 3 4 5 Prior Issue >
As published Thursday, May 28, 2015

By Stephen Parmley, Senior Writer

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants.

The pathway was identified by a group at the La Jolla Institute for Allergy & Immunology, which found that activation of a receptor phosphatase on synovial fibroblasts reduced the cells' pathological activity.